ClinicalTrials.gg
CompletedNCT03487445Updated Jul 29, 2026Results posted

A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack

A Phase 2 interventional study of Selatogrel 8 mg and Selatogrel 16 mg in Acute Myocardial Infarction, sponsored by Viatris Innovation GmbH. Completed at 6 sites in 3 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-07-29.

Sponsored by Viatris Innovation GmbH (part of Viatris Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies in Myocardial Infarction with a site in Switzerland — 14 open to participants now, 20 under way, 5 of them phase 3. Myocardial Infarction · Switzerland.

Enrollment
45th of 51
48 · median 334
Started
2018
with 2 others
Phase 2
7 of 69
none open now
Registered
37th of 69
by date

Among the 69 studies in Myocardial Infarction with a site in Switzerland, this one is the 45th largest by enrollment of the 51 interventional ones that give a count, is one of 3 that started in 2018, is one of 7 in phase 2, and was the 37th registered.

Myocardial Infarction

2,274 studies on the registry are indexed under Myocardial Infarction; 375 are open to participants now.

Browse Myocardial Infarction studies →

Open to participants now

14 of the 69 studies in Myocardial Infarction with a site in Switzerland are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 257 Myocardial Infarction studies recruiting now, 173 (67%) set no upper age limit and 26 (10%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Myocardial Infarction with a site in Switzerland, or all of them as a file.
02

Study summary

The goal of this study is to find out how fast a drug called selatogrel (ACT-246475) can prevent platelets from binding together. This study will also help to find out more about the safety of this new drug. The drug selatogrel (ACT-246475) will be used in 2 different doses (8 mg or 16 mg) and will be administered in the thigh.

Read the detailed description

This study is planned in patients presenting with Acute Myocardial Infarction (AMI) scheduled for an invasive strategy. Platelet activation and thrombus formation play a pivotal role in the pathophysiology of acute coronary syndrome. Early platelet inhibition has been shown to reduce the risk of recurrent events after a myocardial infarction.

The screening period starts when the participant provides informed consent and ends with participant's randomization. Eligible participants had an acute myocardial infarction (AMI; ST-segment elevation myocardial infarction [STEMI] or non-ST-elevation myocardial infarction [NSTEMI]), a life-threatening condition, and will therefore fulfill the ICH-GCP definition of vulnerable subjects ("persons in emergency situations"). Accordingly, a specific process for obtaining consent in compliance with local regulations and approved by the independent ethics committee will be implemented.

The study will be performed during a participant's hospital stay related to the qualifying AMI.

Standard treatment of AMI is allowed including anticoagulants. Ticagrelor will be the only oral P2Y12 receptor antagonist allowed to be initiated during the study and its administration will be possible only after selatogrel administration. Use of fibrinolytics or GPIIb/IIIa inhibitors will be prohibited unless required for bail-out. All other standard-of-care treatments for AMI will be allowed without restriction.

The treatment period starts with the participant's randomization and ends after the end-of-study assessments, approximately 48 hours after the administration of a single study treatment dose.

03

Conditions studied

  • Acute Myocardial Infarction
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • obtained prior to any study-mandated procedure,
  • Males aged from 18 to 85 and females aged up to 85 years,
  • Onset of symptoms of AMI of more than 30 min and less than 6 hours prior to randomization,
  • Subjects presenting a type I AMI including STEMI or NSTEMI.

Main Exclusion Criteria:

  • Cardiogenic shock or severe hemodynamic instability,
  • Cardiopulmonary resuscitation,
  • Loading dose of any oral P2Y12 receptor antagonist prior to randomization,
  • Planned fibrinolytic therapy or any fibrinolytic therapy administered within 24 h prior to randomization,
  • Known disorders (e.g., thromboasthenia, thrombocytopenia, von Willebrand disease).
  • Active internal bleeding, or bleeding diathesis or conditions associated with high risk of bleeding.
  • Known anemia.
  • Oral anticoagulation therapy within 7 days prior to randomization
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Selatogrel 8 mg

    Selatogrel (ACT-246475) is given as a single subcutaneous dose of 8 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.

    Drug: Selatogrel 8 mg

  • Experimental
    Selatogrel 16 mg

    Selatogrel (ACT-246475) is given as a single subcutaneous dose of 16 mg administered in a volume of 0.8 mL. Administration will be performed at the investigational site by qualified personnel.

    Drug: Selatogrel 16 mg

Interventions

  • Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water and further diluted with 1 mL sodium chloride (NaCl) 0.9%.

    Also known as: ACT-246475

  • Selatogrel is a reversible P2Y12 receptor antagonist for subcutaneous administration. It is supplied in sealed glass vials at a strength of 20 mg. The vials with ACT-246475A (hydrochloride salt of ACT-246475) will be reconstituted with 1 mL of water for injection.

    Also known as: ACT-246475

06

What researchers measure

Primary outcomes

  1. Number of Participants With a Pharmacodynamic Response as Assessed by the Inhibition of Platelet Aggregation

    The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using the VerifyNow® assay. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU).The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU less than 100 at 30 minutes post-dose was counted as a participant that had a pharmacodynamic response.

    Time frame: 30 minutes after the administration of the subcutaneous injection

Other outcomes

  1. Number of Participants (Per-protocol Subgroup) With a Pharmacodynamic Response as Assessed by the Inhibition of Platelet Aggregation

    The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU). The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU of less than 100 starting at 30 minutes post-dose was counted as a participant that had a pharmacodynamic response.

    Time frame: 30 minutes after the administration of the subcutaneous injection

  2. Number of Participants With a Pharmacodynamic Response Within the First Hour as Assessed by the Inhibition of Platelet Aggregation

    The purpose of this supportive analysis was to assess the effect when relaxing the time of a PRU \< 100, i.e., considering as a response a PRU \< 100 at 15, 30 or 60 min. post injection. The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using the VerifyNow® assay. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU).The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU less than 100 post-dose was counted as a participant that had a pharmacodynamic response.

    Time frame: pre-dose, 15, 30 and 60 minutes after the administration of the subcutaneous injection

  3. Absolute Platelet Reactivity (P2Y12 Reaction Units) Over Time

    The pharmacodynamic response assessed by the inhibition of adenosine diphosphate (ADP)-mediated platelet aggregation was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test. The results are expressed as P2Y12 reaction units (PRU).

    Time frame: pre-dose, 15, 30 and 60 minutes after administration of the subcutaneous injection

  4. Maximum Selatogrel Plasma Concentration (Cmax)

    The Cmax is the peak concentration of selatogrel in the plasma after subcutaneous injection. The pharmacokinetic parameters of selatogrel (ACT-246475) were derived by non-compartmental analyses of the plasma concentration-time profiles.

    Time frame: pre-dose, 15, 30 and 60 minutes and 8 hours after the administration of the subcutaneous injection

  5. Time to Reach Maximum Selatogrel Plasma Concentration (Tmax)

    Time after subcutaneous injection to reach the maximum observed selatogrel plasma concentration (Cmax).

    Time frame: pre-dose, 15, 30 and 60 minutes and 8 hours after the administration of the subcutaneous injection

07

Results

Posted Aug 25, 2021
Limitations and caveats
The p-values need to be cautiously interpreted due to the small study population size. The participants were expected per protocol to shortly undergo invasive management, it was anticipated that most would receive an early loading dose of ticagrelor. Blood samples were collected with phenylalanine-proline-arginine-chloromethylketone as anticoagulant. Only the VerifyNow® assay was used to assess the platelet response to selatogrel.

Participant flow

The study was conducted between 10 July and 10 November 2018. Seven sites were initiated. Six sites in 3 countries screened and randomized 48 participants.

Randomization
Participant flow — Randomization
MilestoneSelatogrel 8 mgSelatogrel 16 mg
Started2523
Completed2423
Not completed10
Withdrew: Not treated for administrative reasons10
Treatment Period
Participant flow — Treatment Period
MilestoneSelatogrel 8 mgSelatogrel 16 mg
Started2423
Modified full analysis set (mfas)2322
Per protocol set2020
Completed2423
Not completed00

Outcome measures

PrimaryNumber of Participants With a Pharmacodynamic Response as Assessed by the Inhibition of Platelet Aggregation

The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using the VerifyNow® assay. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU).The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU less than 100 at 30 minutes post-dose was counted as a participant that had a pharmacodynamic response.

Time frame:
30 minutes after the administration of the subcutaneous injection
Reported as:
Number · Count of participants
Number of Participants With a Pharmacodynamic Response as Assessed by the Inhibition of Platelet Aggregation
Count of participantsSelatogrel 8 mgSelatogrel 16 mg
Number of Participants With a Pharmacodynamic Response as Assessed by the Inhibition of Platelet Aggregation2121
Statistical analysis
  • Selatogrel 8 mg · one-sided z-test · p = <0.001 (P-value for hypotheses (H0: p \<= 50% vs. H1: p \> 50%))A p-value significance level was set to 0.025.
  • Selatogrel 8 mg · one-sided z-test · p = 0.142 (P-value for hypotheses (H0: p \<= 85% vs. H1: p \> 85%))A p-value significance level was set to 0.025, an overall level of 0.05 and adjusted for multiplicity using the Bonferroni approach.
  • Selatogrel 16 mg · one-sided z-test · p = <0.0001 (P-value for hypotheses (H0: p \<= 50% vs. H1: p \> 50%))A p-value significance level was set to 0.025.
  • Selatogrel 16 mg · one-sided z-test · p = 0.009 (P-value for hypotheses (H0: p \<= 85% vs. H1: p \> 85%))A p-value significance level was set to 0.025, an overall level of 0.05 and adjusted for multiplicity using the Bonferroni approach.
Other pre-specifiedNumber of Participants (Per-protocol Subgroup) With a Pharmacodynamic Response as Assessed by the Inhibition of Platelet Aggregation

The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU). The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU of less than 100 starting at 30 minutes post-dose was counted as a participant that had a pharmacodynamic response.

Time frame:
30 minutes after the administration of the subcutaneous injection
Reported as:
Number · Count of participants
Number of Participants (Per-protocol Subgroup) With a Pharmacodynamic Response as Assessed by the Inhibition of Platelet Aggregation
Count of participantsSelatogrel 8 mgSelatogrel 16 mg
Number of Participants (Per-protocol Subgroup) With a Pharmacodynamic Response as Assessed by the Inhibition of Platelet Aggregation1819
Statistical analysis
  • Selatogrel 8 mg · One-sided Z-test · p = 0.2280 (P-value for hypotheses (H0: p \<= 85% versus H1: p \> 85%))
  • Selatogrel 16 mg · One-sided Z-test · p = 0.0201 (P-value for hypotheses (H0: p \<= 85% versus H1: p \> 85%))
Other pre-specifiedNumber of Participants With a Pharmacodynamic Response Within the First Hour as Assessed by the Inhibition of Platelet Aggregation

The purpose of this supportive analysis was to assess the effect when relaxing the time of a PRU \< 100, i.e., considering as a response a PRU \< 100 at 15, 30 or 60 min. post injection. The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using the VerifyNow® assay. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU).The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU less than 100 post-dose was counted as a participant that had a pharmacodynamic response.

Time frame:
pre-dose, 15, 30 and 60 minutes after the administration of the subcutaneous injection
Reported as:
Number · Count of participants
Number of Participants With a Pharmacodynamic Response Within the First Hour as Assessed by the Inhibition of Platelet Aggregation
Count of participantsSelatogrel 8 mgSelatogrel 16 mg
pre-dose10
15 minutes post-dose1821
30 minutes post-dose2121
60 minutes post-dose1822
Other pre-specifiedAbsolute Platelet Reactivity (P2Y12 Reaction Units) Over Time

The pharmacodynamic response assessed by the inhibition of adenosine diphosphate (ADP)-mediated platelet aggregation was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test. The results are expressed as P2Y12 reaction units (PRU).

Time frame:
pre-dose, 15, 30 and 60 minutes after administration of the subcutaneous injection
Reported as:
Median · P2Y12 reaction units (PRU)
Absolute Platelet Reactivity (P2Y12 Reaction Units) Over Time
P2Y12 reaction units (PRU)Selatogrel 8 mgSelatogrel 16 mg
pre-dose194 (159 to 213)181 (148 to 213)
15 minutes post-dose51 (4 to 208)9 (2 to 282)
30 minutes post-dose59 (2 to 135)9 (2 to 117)
60 minutes post-dose9 (2 to 116)7 (1 to 228)
Other pre-specifiedMaximum Selatogrel Plasma Concentration (Cmax)

The Cmax is the peak concentration of selatogrel in the plasma after subcutaneous injection. The pharmacokinetic parameters of selatogrel (ACT-246475) were derived by non-compartmental analyses of the plasma concentration-time profiles.

Time frame:
pre-dose, 15, 30 and 60 minutes and 8 hours after the administration of the subcutaneous injection
Reported as:
Geometric mean · ng/mL
Maximum Selatogrel Plasma Concentration (Cmax)
ng/mLSelatogrel 8 mgSelatogrel 16 mg
Maximum Selatogrel Plasma Concentration (Cmax)390.1 (206 to 848)672.6 (276 to 1180)
Other pre-specifiedTime to Reach Maximum Selatogrel Plasma Concentration (Tmax)

Time after subcutaneous injection to reach the maximum observed selatogrel plasma concentration (Cmax).

Time frame:
pre-dose, 15, 30 and 60 minutes and 8 hours after the administration of the subcutaneous injection
Reported as:
Median · hours
Time to Reach Maximum Selatogrel Plasma Concentration (Tmax)
hoursSelatogrel 8 mgSelatogrel 16 mg
Time to Reach Maximum Selatogrel Plasma Concentration (Tmax)1.00 (0.50 to 1.27)0.97 (0.25 to 1.15)
Post-hocSubgroup Analyses: Number of Participants With a Pharmacodynamic Response as Assessed by the Inhibition of Platelet Aggregation

The pharmacodynamic response was determined by measuring the inhibition of platelet aggregation, using VerifyNow®. The VerifyNow® is a point-of-care test measuring platelet reactivity. The results are expressed as P2Y12 reaction units (PRU). The target of 100 PRU corresponds to 80% inhibition of ADP-induced platelet aggregation. A participant with a PRU of less than 100 starting at 30 minutes post-dose was counted as a participant that had a pharmacodynamic response.

Time frame:
30 minutes after the administration of the subcutaneous injection
Reported as:
Number · Count of participants
Subgroup Analyses: Number of Participants With a Pharmacodynamic Response as Assessed by the Inhibition of Platelet Aggregation
Count of participantsSelatogrel 8 mgSelatogrel 16 mg
Age less than 55 years old34
Age 55 years and older1817
Male1417
Female74
Body Mass Index less than 2558
Body Mass Index less than 25 and up to 3089
Body Mass Index greater than 3084
Diabetes mellitus at baseline85
No diabetes mellitus at baseline1316
Chronic kidney disease at baseline—3
No Chronic kidney disease at baseline2118
STEMI at baseline1411
NSTEMI at baseline710

Adverse events

Collected over Treatment emergent adverse events (TEAEs) were those adverse events with onset after study drug administration and up to 48 hours after study treatment administration.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Selatogrel 8 mg0/24 (0%)1/24 (4.2%)12/24 (50%)
Selatogrel 16 mg0/23 (0%)1/23 (4.3%)7/23 (30.4%)
Most frequent serious events
Most frequent serious events
EventSelatogrel 8 mgSelatogrel 16 mg
Ventricular tachycardiaCardiac disorders1/241/23
Most frequent other events
Showing 10 of 23
Most frequent other events
EventSelatogrel 8 mgSelatogrel 16 mg
Ventricular tachycardiaCardiac disorders3/242/23
DyslipidaemiaMetabolism and nutrition disorders3/242/23
Aortic stenosisVascular disorders0/241/23
Cardiac failureCardiac disorders0/241/23
Mitral valve stenosisCardiac disorders0/241/23
DyspnoeaRespiratory, thoracic and mediastinal disorders0/241/23
Pleural effusionRespiratory, thoracic and mediastinal disorders0/241/23
DizzinessNervous system disorders0/241/23
Confusional statePsychiatric disorders0/241/23
Herpes zosterInfections and infestations0/241/23

Baseline characteristics

Full Analysis Set (all participants that were treated).

Age, Categorical
Age, Categorical(Participants)Selatogrel 8 mgSelatogrel 16 mgTotal
Full Analysis Set — <=18 years000
Full Analysis Set — Between 18 and 65 years9817
Full Analysis Set — >=65 years151530
Per Protocol Set — <=18 years000
Per Protocol Set — Between 18 and 65 years9716
Per Protocol Set — >=65 years111324
Age, Continuous
Age, Continuous(years)Selatogrel 8 mgSelatogrel 16 mgTotal
Full Analysis Set65.5 ± 11.368.0 ± 10.366.7 ± 10.8
Per Protocol Set64.5 ± 12.167.9 ± 10.366.2 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)Selatogrel 8 mgSelatogrel 16 mgTotal
Full Analysis Set — Female8513
Full Analysis Set — Male161834
Per Protocol Set — Female549
Per Protocol Set — Male151631
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Selatogrel 8 mgSelatogrel 16 mgTotal
Full Analysis Set — Hispanic or Latino000
Full Analysis Set — Not Hispanic or Latino242347
Full Analysis Set — Unknown or Not Reported000
Per Protocol Set — Hispanic or Latino000
Per Protocol Set — Not Hispanic or Latino202040
Per Protocol Set — Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Selatogrel 8 mgSelatogrel 16 mgTotal
Full Analysis Set — American Indian or Alaska Native000
Full Analysis Set — Asian123
Full Analysis Set — Native Hawaiian or Other Pacific Islander000
Full Analysis Set — Black or African American000
Full Analysis Set — White222143
Full Analysis Set — More than one race000
Full Analysis Set — Unknown or Not Reported101
Per Protocol Set — American Indian or Alaska Native000
Per Protocol Set — Asian123
Per Protocol Set — Native Hawaiian or Other Pacific Islander000
Per Protocol Set — Black or African American000
Per Protocol Set — White181836
Per Protocol Set — More than one race000
Per Protocol Set — Unknown or Not Reported101
Region of Enrollment
Region of Enrollment(participants)Selatogrel 8 mgSelatogrel 16 mgTotal
Belgium7714
Israel101
Switzerland161632
Body Mass Index
Body Mass Index(kilograms per square meter)Selatogrel 8 mgSelatogrel 16 mgTotal
Full Analysis Set28.00 ± 4.8326.78 ± 3.7427.40 ± 4.33
Per Protocol Set27.64 ± 4.8826.67 ± 3.7927.16 ± 4.34
Medical history risk factors at baseline
Medical history risk factors at baseline(Participants)Selatogrel 8 mgSelatogrel 16 mgTotal
Diabetes mellitus8513
Chronic Kidney disease033
Hypertension151227
Dyslipidemia81018

4 further baseline measures are reported on the registry.

08

Study locations

6 sites
  • OLV Ziekenhuis Aalst
    Aalst, 9300, Belgium
  • UZLeuven
    Leuven, 3000, Belgium
  • Galilee Medical Center
    Nahariya, 22100, Israel
  • Universitätsspital Basel
    Basel, 4031, Switzerland
  • University Hospital Bern
    Bern, 3010, Switzerland
  • Cardiocentro Ticino
    Lugano, 6900, Switzerland
09

References and documents

Publications

  • Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R, Rasmussen L, Storey RF, Nielsen T, Eikelboom JW, Sabe-Affaki G, Husted S, Kereiakes DJ, Henderson D, Patel DV, Tantry US. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation. 2010 Mar 16;121(10):1188-99. doi: 10.1161/CIRCULATIONAHA.109.919456. Epub 2010 Mar 1. PubMed 20194878 ↗
  • Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L. Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. Eur Heart J. 2006 May;27(10):1166-73. doi: 10.1093/eurheartj/ehi877. Epub 2006 Apr 18. PubMed 16621870 ↗
  • Parodi G, Bellandi B, Valenti R, Migliorini A, Marcucci R, Carrabba N, Giurlani L, Gensini GF, Abbate R, Antoniucci D. Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study. Am Heart J. 2014 Jun;167(6):909-14. doi: 10.1016/j.ahj.2014.03.011. Epub 2014 Apr 4. PubMed 24890542 ↗
  • Sinnaeve P, Fahrni G, Schelfaut D, Spirito A, Mueller C, Frenoux JM, Hmissi A, Bernaud C, Ufer M, Moccetti T, Atar S, Valgimigli M. Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction. J Am Coll Cardiol. 2020 May 26;75(20):2588-2597. doi: 10.1016/j.jacc.2020.03.059. PubMed 32439008 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Nov 2018, 4 months.

Results were first posted in Aug 2021, 2 years 9 months after primary completion. A results delay was requested in Aug 2019.

Of 45 phase 2 interventional studies under Myocardial Infarction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 42. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 26, 2018
First posted
Apr 4, 2018
StartActual
Jul 10, 2018
Primary completionActual
Nov 10, 2018
CompletionActual
Nov 10, 2018
Results delay requested
Aug 14, 2019
Results first posted
Aug 25, 2021
Last update
Jul 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03487445
Responsible party
Sponsor
First posted
Apr 4, 2018
Start date
Jul 10, 2018
Primary completion
Nov 10, 2018
Completion
Nov 10, 2018
Results posted
Aug 25, 2021
Last update
Jul 29, 2026

Study contacts

Clinical Trials
study director · Viatris Innovation GmbH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Selatogrel

Start the discussion